All In Biotech

Drug Trial Radar · NCT03294577

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

A Phase 3, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in the Prevention of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)

Last checked: Nov 19, 2026Latest source record: Jan 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 221 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

221

Actual

Start

Oct 23, 2019

Primary completion

Sep 25, 2020

Study completion Sep 25, 2025

Sponsor

Sponsor type
Industry
First posted
Sep 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Supportive care
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to compare the percentage of patients with Duration of Severe Neutropenia (DSN) =0 in patients treated with: Docetaxel, doxorubicin, and cyclophosphamide (TAC) + pegfilgrastim versus Docetaxel, doxorubicin, and cyclophosphamide (TAC) + combination plinabulin/pegfilgrastim Severe neutropenia is an absolute neutrophil count (ANC) \<0.5 × 10\^9/L. Docetaxel, doxorubicin, and cyclophosphamide (TAC) will be used as the chemotherapy in this study.

Conditions

  • Chemotherapy-induced Neutropenia

Interventions

  • PegfilgrastimDrug

    PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

  • PlinabulinDrug

    Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

  • D5W PlaceboOther

    Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W

  • Docetaxel, doxorubicin, and cyclophosphamide (TAC)Drug

    Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of patients with Duration of Severe Neutropenia (DSN) =0Time frame: Duration of Grade 4 neutropenia assessed during the first cycle (21 days)

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • No. 1 Banshandong Road

    Hangzhou, Gongshu District, China

  • Cancer Center of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Cancer Center of Guangzhou Medical University Breast Oncology

    Guangzhou, Guangzhou, China

  • Harbin Medical University Cancer Hospital

    Harbin, Harbin, China

  • Fourth Hospital of Hebei Medical University Breast cancer department

    Shijiazhuang, Hebei, China

  • China-Japan Union Hospital of Jilin University Tumor department of Hematology

    Changchun, Jilin, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, Shenyang, China

  • Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department

    Dnipro, Ukraine

  • Prykarpatskiy Regional Oncological Center

    Ivano-Frankivsk, Ukraine

  • Regional Clinical Oncology Center

    Kharkiv, Ukraine

  • V.T. Zaycev Institute

    Kharkiv, Ukraine

  • Kirovograd Regional Oncological Center

    Kropyvnytskyi, Ukraine

  • Public Institution Kryvyi Rih Oncology Center

    Krutyi Bereh, Ukraine

  • Hemotherapy Department

    Kyiv, Ukraine

  • Kyiv City Clinical Oncological Center

    Kyiv, Ukraine

  • Lviv State Oncological Regional

    Lviv, Ukraine

  • Odessa regional clinical hospital Thoracic Surgery Department Academician Zabolotnoho

    Odesa, Ukraine

  • Zakarpattia Regional Clinical Oncology Center

    Uzhhorod, Ukraine

  • Vinnytsya Regional Clinical Oncology Dispensary

    Vinnytsia, Ukraine

  • Zaporizhia Regional Clinical Oncology Dispensary

    Zaporizhzhya, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.